Robb Gary Charles's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Jan 6, 2025
- Accession no.
- 0000950170-25-002439
- Filed
- Jan 6, 2025
- Trade date
- Jan 2-3, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $555.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Robb Gary CharlesCIK 0001529655 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | Common Stock | MOption exerciseAcquired | +11,000 | $3.29 | +$36,190 | 31,119 | Direct | |
| Jan 2, 2025 | Common Stock | SSaleDisposed | −11,000 | $50.50F3 | −$555,500 | 20,119 | Direct | |
| Jan 3, 2025 | Common Stock | MOption exerciseAcquired | +3,037 | $3.29 | +$9,991.73 | 23,156 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | Common Stock | MOption exerciseDisposed | −11,000 | $0.00 | $0 | 3,037 | Direct | |
| Jan 3, 2025 | Common Stock | MOption exerciseDisposed | −3,037 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.39 to $50.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.